Migraine Treatment in Pregnancy and Lactation
- 1.3k Downloads
Purpose of Review
Since up to 40.9% of reproductive aged women have migraine—and reproductive-aged women often reproduce—it is essential that we have good information and guidelines regarding proper treatment of migraine during pregnancy and lactation.
A review of articles published in the last year on the treatment of migraine during pregnancy and lactation found dishearteningly little. Nevertheless, this article will review the risk/safety information related to migraine treatment in both pregnancy and lactation, citing both new and less recent publications.
There is little if any formal research is being carried out on pharmacotherapy for migraine that occurs during pregnancy or lactation. This is likely due to two issues: (1) neurology offers little training in female sex hormones, while gynecology is a surgical field; (2) there is the ever-present concern of litigation if any bad outcome occurs, yet there is no designation of “legally safe” that can be applied to a drug’s use in pregnancy and lactation.
KeywordsMigraine Treatment Pregnancy Lactation
Compliance with Ethical Standards
Conflict of Interest
The author declares that she has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•• Amundsen S, Øvrebø TG, Amble NM, Poole AC, Nordeng H. Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women. Eur J Clin Pharmacol. 2016;72(12):1525–35. This article highlights the problem of inadequate authoritative guidance for treatment of migraine inpregnancy and lactation CrossRefPubMedGoogle Scholar
- 9.Matt DW, Borzelleca JF. Toxic effects on the female reproductive system during pregnancy, parturition, and lactation. In: Witorsch RJ, editor. Reproductive toxicology. 2d ed. New York: Raven; 1995. p. 175–93.Google Scholar
- 10.Collins E. Maternal and fetal effects of acetaminophen and salicylates in pregnancy. Obstet Gynecol. 1981;585(Suppl):57S–62S.Google Scholar
- 15.European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC): minutes of the meeting on 5–8 May 2014. PRAC: Agendas, minutes and highlights [online], http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2014/06/WC500169468.pdf (2014).
- 23.Sumatriptan [package insert] GlaxoSmithKline, Inc. 2013 [cited 2017 March 5]; Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Imitrex_Nasal_Spray/pdf/IMITREX-NASAL-SPRAY-PI-PIL.PDF.
- 29.Calhoun AH, Ford S, Finkel A, Kahn D, Mann JD. The prevalence and spectrum of sleep problems in women with transformed migraine. Headache. 2006;46(4):604-10.Google Scholar
- 31.• Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 9th ed. Philadelphia: Lippincott Wilkins and Williams; 2011.Google Scholar
- 32.• Hale TW. Medications and mothers’ milk. 16th ed. Amarillo: Hale Publishing; 2014.Google Scholar
- 35.Relpax (eletriptan hydrobromide) [product monograph]. Kirkland, QC: Pfizer; 2004.Google Scholar